Share this article
Share this article
HOUSTON, May 25, 2021 /PRNewswire/ AuraVax Therapeutics, Inc. (Auravax), a biotech company developing novel intranasal therapeutics and vaccines to help patients defeat debilitating respiratory diseases, including COVID-19, today announced the formation of its inaugural Scientific Advisory Board (SAB), consisting of leading experts in the fields of biology, vaccines and intranasal drug delivery. The SAB will guide and advise the company in its ongoing development of proprietary therapeutics and vaccines for respiratory diseases.
The SAB is chaired by George M. Church, Ph.D. and includes Stephen Albert Johnston from Calviri, Inc and Mei X. Wu, Ph.D. from Massachusetts General Hospital/Harvard Medical School.